Circulating Tumor Cell Dx Is Technology To Watch In 2009 – Cleveland Clinic
This article was originally published in The Gray Sheet
Executive Summary
Use of circulating tumor cell assays to predict chemotherapy success will be the most significant medical innovation to break through in 2009, a panel of Cleveland Clinic physicians predicts
You may also be interested in...
Bone Conduction Hearing Device Is Tech To Watch In 2010 - Cleveland Clinic
Devices that allow people with single-sided deafness to regain hearing by transmitting sound through the teeth will be the most significant medical innovation to take off in 2010, a panel of Cleveland Clinic physicians predicts
Bone Conduction Hearing Device Is Tech To Watch In 2010 - Cleveland Clinic
Devices that allow people with single-sided deafness to regain hearing by transmitting sound through the teeth will be the most significant medical innovation to take off in 2010, a panel of Cleveland Clinic physicians predicts
Research In Brief
Abbott DES Trial: Abbott announces start of SPIRIT PRIME, the U.S. clinical trial of its next-generation Xience Prime everolimus-eluting coronary stent, during its July 15 second-quarter earnings call. The company expects to launch Xience Prime in the U.S. in 2012. Abbott recently began shipping Xience Prime to select accounts in Europe following receipt of a CE Mark in June (1"The Gray Sheet" June 29, 2009). Xience Prime is available in a broad range of sizes up to 38 mm. SPIRIT PRIME is a 500-patient, 75-center nonrandomized trial with two arms. The core size arm will follow 400 patients treated with a stent from 2.25 mm to 4.0 mm in diameter and 8 mm to 28 mm in length, and the long lesion arm will follow 100 patients with a stent 2.5 mm to 4.0 mm in diameter and either 33 mm or 38 mm in length. The primary endpoint is major adverse cardiac events